Human Papillomavirus type distribution in invasive cervical cancer in Uganda

doi:10.1186/1471-2334-8-85

BMC Infectious Diseases
Volume 8

Viewing options:

Abstract
Full text
PDF (260KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Odida M
de Sanjosé S
Quint W
Bosch XF
Klaustermeier J
Weiderpass E

on PubMed

Odida M
de Sanjosé S
Quint W
Bosch XF
Klaustermeier J
Weiderpass E
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Research article

Human Papillomavirus type distribution in invasive cervical cancer in Uganda

Michael Odida¹^,2 , Silvia de Sanjosé³ , Wim Quint⁴ , Xavier F Bosch³ , Joellen Klaustermeier³ and Elisabete Weiderpass²^,5^,6

¹Department of Pathology, Faculty of Medicine, Makerere University, Kampala, Uganda

²Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

³Unit of Infections and Cancer, Catalan Institute of Oncology, Barcelona, Spain

⁴DDL Diagnostic Laboratory, Voorburg, The Netherlands

⁵Department of Etiological Research, The Cancer Registry of Norway, Oslo, and Department of Community Medicine, Tromso University, Norway

⁶Department of Genetic Epidemiology, Samfunded Folkhalsan, Helsinki, Finland

author email corresponding author email

BMC Infectious Diseases 2008, 8:85doi:10.1186/1471-2334-8-85


Published:	24 June 2008

Abstract

Background

We conducted a study aiming to describe Human Papillomavirus (HPV) type distribution in invasive cervical carcinoma in Uganda.

Methods

191 archival cervical carcinoma samples diagnosed in the Department of Pathology, Makerere University in Kampala between 1968 and 1992 were analysed using a sensitive PCR-Reverse Hybridization Line Probe Assay.

Results

Out of the 186 cases of confirmed invasive cervical cancer in the study paraffin blocks, 114 were positive for HPV DNA. Specific HPV genotypes were identifiable in 109 cases: HPV 16, 18, 31, 35, 39, 44, 45, 51, 52 and 70. These occurred as single infections in 105 cases (96.3%) and as multiple infections in 4 cases (3.7%). HPV 16 or 18 accounted for 80% (84/105) of cases with single infection.

Conclusion

The results of this study confirm the role of HPV 16 and 18 in cervical cancer pathogenesis in the Ugandan population. The results suggest that the currently available HPV vaccines against HPV 16 and 18 could possibly prevent the majority of invasive cervical cancers in Uganda.